Huashan Hospital of the Shanghai FuDan University
Shanghai, Shanghai Municipality, 200433, China
NCT Number: NCT05055934
This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 111 adult subjects with psoriatic arthritis.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Shanghai, Shanghai Municipality, 200433, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SHR-1314 injection
placebo
Time frame: at week 12
Time frame: week 12
Time frame: week 12
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Industry
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploratory Study to Evaluate the Effectiveness and Safety of SHR-1314 Injection in Adult Subjects With Active Psoriatic Arthritis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05616871
Arthritis, Arthritis, Psoriatic
Nice, Alpes-Maritimes, France
View Trial DetailsNCT03895203
Arthritis, Arthritis, Psoriatic
Phoenix, Arizona, United States
View Trial DetailsNCT03896581
Arthritis, Arthritis, Psoriatic
Phoenix, Arizona, United States
View Trial DetailsNCT04009499
Arthritis, Arthritis, Psoriatic
Phoenix, Arizona, United States
View Trial Details